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ABSTRACT Bacteria utilize complex type IV secretion systems (T4SSs) to translocate diverse effector proteins or DNA into tar-
get cells. Despite the importance of T4SSs in bacterial pathogenesis, the mechanism by which these translocationmachineries
deliver cargo across the bacterial envelope remains poorly understood, and very few studies have investigated the use of syn-
thetic molecules to disrupt T4SS-mediated transport. Here, we describe two synthetic small molecules (C10 and KSK85) that
disrupt T4SS-dependent processes in multiple bacterial pathogens.Helicobacter pylori exploits a pilus appendage associated
with the cag T4SS to inject an oncogenic effector protein (CagA) and peptidoglycan into gastric epithelial cells. InH. pylori,
KSK85 impedes biogenesis of the pilus appendage associated with the cag T4SS, while C10 disrupts cag T4SS activity without
perturbing pilus assembly. In addition to the effects inH. pylori, we demonstrate that these compounds disrupt interbacterial
DNA transfer by conjugative T4SSs in Escherichia coli and impede vir T4SS-mediated DNA delivery by Agrobacterium tumefa-
ciens in a plant model of infection. Of note, C10 effectively disarmed dissemination of a derepressed IncF plasmid into a recipi-
ent bacterial population, thus demonstrating the potential of these compounds in mitigating the spread of antibiotic resistance
determinants driven by conjugation. To our knowledge, this study is the first report of synthetic small molecules that impair
delivery of both effector protein and DNA cargos by diverse T4SSs.
IMPORTANCE Many human and plant pathogens utilize complex nanomachines called type IV secretion systems (T4SSs) to
transport proteins and DNA to target cells. In addition to delivery of harmful effector proteins into target cells, T4SSs can dis-
seminate genetic determinants that confer antibiotic resistance among bacterial populations. In this study, we sought to identify
compounds that disrupt T4SS-mediated processes. Using the human gastric pathogenH. pylori as a model system, we identified
and characterized two small molecules that prevent transfer of an oncogenic effector protein to host cells. We discovered that
these small molecules also prevented the spread of antibiotic resistance plasmids in E. coli populations and diminished the
transfer of tumor-inducing DNA from the plant pathogen A. tumefaciens to target cells. Thus, these compounds are versatile
molecular tools that can be used to study and disarm these important bacterial machines.
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Numerous bacterial species translocate effector molecules intotarget cells to subvert host defense mechanisms and hijack
cellular processes. Delivery of bacterial effectors can be achieved
using elaborate secretion systems that are assembled in response
to specific environmental stimuli, such as direct bacterial contact
with target cells (1). Type IV secretion systems (T4SSs) are ex-
traordinarily versatile contact-dependent cargo delivery systems
that are both phylogenetically and functionally diverse (2). These
membrane-spanning systems are composed of conserved core
complex subunits, as well as species-specific components that af-
ford apparatus specialization and facilitate occupation of specific
intracellular and extracellular niches (3–5).
T4SSs can be divided into three subfamilies: (i) DNA conjuga-
tion machines, (ii) DNA uptake/release systems that exchange
DNA with the extracellular milieu, and (iii) effector translocator
systems (2, 6, 7). T4SSs contribute to the pathogenesis of disease
caused by several human pathogens, including Brucella, Barto-
nella,Coxiella,Rickettsia, Legionella pneumophila,Helicobacter py-
lori, and phytopathogens such asAgrobacterium tumefaciens (1, 3).
Elegant studies of the prototypical vir T4SS effector translocator
system inA. tumefaciens (4, 8, 9) have laid the groundwork for the
study of T4SSs in other bacterial species, including the distantly
related cag T4SS that is harbored by virulent strains of the gastric
bacterium H. pylori (10–12).
H. pylori can persist within the human gastric mucosa, often
for the lifetime of the individual. Although the majority of H. py-
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lori-infected individuals remain asymptomatic, colonization by
H. pylori is associated with a broad range of clinical outcomes
ranging from non-atrophic gastritis to severe disorders including
gastric and duodenal ulcers and gastric adenocarcinoma (13).
These severe gastric diseases occur more frequently in individuals
who are colonized by H. pylori strains that produce a T4SS en-
coded by the 40-kb cag pathogenicity island (cag PAI) (11). The
cag T4SS translocates the oncogenic bacterial protein CagA (10,
12, 14), as well as peptidoglycan (15), directly into the cytoplasm
of gastric epithelial cells. One consequence of cag T4SS activity is
NF-B activation (16, 17) and increased production of proinflam-
matory cytokines such as interleukin 8 (IL-8) (18). However, we
lack a fundamental understanding of cag T4SS apparatus assem-
bly, and themechanisms ofCagA translocation and peptidoglycan
delivery remain unresolved (10–12, 14).
When in contact with human gastric epithelial cells, H. pylori
produces filamentous structures at the bacterium-host cell inter-
face. Formation of these structures requires several genes carried
on the cag PAI (19–22). These structures are thought to be an
extracellular portion of the cag T4SS, analogous to the F pilus in
conjugative T4SSs, and thus, these H. pylori structures have been
termed cag T4SS pili (19–21). The composition of cag T4SS pili is
not well defined, but several cag PAI-encoded proteins have been
reported to localize to the pilus (21–24). The effector protein
CagA has been localized at or near the tips of cag T4SS pili (21, 24,
25), and H. pylori mutants that fail to produce pili are unable to
translocateCagA (19, 20, 24, 25), indicating that cagT4SS pili have
an important role inT4SS function. In contrast to the requirement
of pili for the actions of the H. pylori cag T4SS, the delivery of
A. tumefaciens oncogenic plasmid-derived transfer DNA (T-
DNA) to target plant cells does not require biogenesis of the vir
T4SS-associated T-pilus (8, 26, 27). Although the structures of
related Escherichia coli conjugative T4SSs have been resolved (6,
7), the precise mechanism of DNA transport across the bacterial
envelope remains elusive.
Chemical genetics enable the dissection of processes through
the use of small-molecule inhibitors, which offer temporal control
and reversibility (28). Thus far, there are very few chemical tools
available for the study of T4SS-dependent processes in H. pylori.
One study reported the discovery of salicylidene acylhydrazide
inhibitors of the Brucella assembly factor VirB8, but the applica-
bility of these compounds to other T4SSs has not been reported
(29, 30). Other groups have reported identification of small mol-
ecules that inhibit the VirB11 ATPase of the cag T4SS (31, 32), but
because these compounds are ATP mimetics that may inhibit
other cellular ATPases, their utility for enhancing our under-
standing of cag T4SS apparatus assembly is limited.
We previously published a significant body of work describing
the development of peptidomimetic small molecules (termed pi-
licides) that disrupted chaperone-usher pathway (CUP) pilus for-
mation in E. coli (33–37). Structurally, these compounds con-
tained a central ring-fused 2-pyridone peptidomimetic fragment
(33, 34). Utilizing a compound library based around this scaffold,
we performed a phenotypic screen for compounds that affected
function or assembly of theH. pylori cag T4SS. We identified two
closely related analogues, C10 and KSK85 that attenuated the de-
livery of peptidoglycan and CagA to host cells. We show that the
T4SS targeting effects of C10 and KSK85 are not limited toH. py-
lori; C10 and KSK85 also inhibit interbacterial conjugative T4SS-
mediated DNA transfer in E. coli and impair vir T4SS-dependent
T-DNA delivery by A. tumefaciens in a plant model of infection.
Moreover, we demonstrate that while KSK85 impairs formation
of H. pylori cag T4SS-associated pili, C10 impairs T4SS-mediated
transport without impacting T4SS pilus biogenesis. Thus, these
small molecules can be used to dissect the assembly of T4SSs in
divergent proteobacteria.
RESULTS
Identification of small molecules that disruptH. pylori cag type
IV effector delivery. A functionally active cag T4SS in H. pylori
induces secretion of the proinflammatory cytokine IL-8 and acti-
vation of NF-B signaling whenH. pylori is co-cultured with gas-
tric epithelial cells (16–18, 38). We screened a series of peptido-
mimetic small molecules (see Table S1 in the supplemental
material) for their capacity to inhibit secretion of IL-8 and activa-
tion of NF-B signaling in H. pylori-gastric epithelial cell culture
(Fig. 1; see Fig. S1A in the supplemental material). This focused
library consisted of 22 compounds from our in-house collection
that contain a central peptidomimetic 2-pyridone motif (Ta-
ble S1). In addition to compounds known to affect the assembly of
type 1 pili or curli in E. coli (e.g., EC240 and FN075) (36, 37, 39),
we included analogues preparedwhen developing syntheticmeth-
odologies (e.g., C10, MS218, and MS383) (40–42) and from
natural-product-inspired diversity-oriented synthesis (e.g.,
MS542 andMS610) (43, 44). None of the compoundswith known
activity against CUP pilus assembly in E. coli affected cag T4SS
activity at the concentrations tested. Two compounds signifi-
cantly reduced cag T4SS-dependent IL-8 secretion and NF-B ac-
tivation (C10 and KSK85 [Table 1]) in a dose-dependent manner
(Fig. 1B andD). The effects of C10 andKSK85were additive when
both compounds were present at equal concentrations inH. pylo-
ri-gastric epithelial cell co-cultures (Fig. 1B, gray line). We in-
cluded an inactive tricyclic analogue GKP42 (Fig. 1A) as a non-
inhibitory compound. GKP42 hadminimal effects or no effect on
IL-8 secretion at the highest concentrations tested (Fig. 1B) and
did not attenuate NF-B activation (Fig. 1D) or exhibit activity in
subsequent assays. Exposure to C10, KSK85, or GKP42 did not
impact viability of gastric epithelial or bacterial cells (Fig. S1B and
S1C) at concentrations up to 150 M.
The inhibition of cagT4SS-mediated IL-8 secretion andNF-B
activation by C10 and KSK85 prompted us to measure CagA de-
livery to gastric epithelial cells. CagA is phosphorylated at con-
served tyrosine residues upon T4SS-dependent translocation into
the host cell (12). Thus, translocated CagA can be detected by
immunoblot analysis probing for the presence of phosphorylated
CagA. Compared to vehicle-only andGKP42-treated controls, ex-
posure to C10 and KSK85 significantly reduced the amount of
tyrosine-phosphorylated CagA detected in cultured gastric epi-
thelial cells (Fig. 1C; see Fig. S1E in the supplemental material).
Compound treatment of AGS gastric epithelial cells in the absence
of bacteria did not affect the ability of the cells to signal through
the canonical tumor necrosis factor alpha (TNF-) pathway,
which leads to activation of NF-B and subsequent synthesis and
secretion of IL-8 (Fig. 1E and F). These compounds did not pre-
vent bacterial adherence to gastric epithelial cells at concentra-
tions ranging from 25 M to 150 M (Fig. S1D), indicating that
the observed reduction in cagT4SS activity was not a consequence
of fewer bacterial cells establishing contact with gastric epithelial
cells. The compounds did not impair type V secretion system-
mediated release of the cytotoxin VacA into cell culture superna-
Shaffer et al.
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tants (Fig. S1F), suggesting that C10 and KSK85 did not broadly
impact bacterial secretory processes. C10 andKSK85 inhibited cag
T4SS-mediated NF-B activation by H. pylori strains of different
phylogeographic origins (Fig. S1G and S1H). These data indicate
that the observed compound effects were not strain specific. Fur-
ther consideration of structure-activity relationships underlying
the capacity of the compounds to inhibit cag T4SS function is
presented in Text S1 in the supplemental material.
KSK85 impairs T4SS-associated pilus formation. The pep-
tidomimetic 2-pyridone scaffold used to generate C10 and KSK85
was designed to ablate pilus biogenesis in uropathogenic E. coli
(35, 36). We therefore investigated the effects of C10 and KSK85
on the assembly of cag T4SS-associated pili at the bacterium-host
cell interface.H. pylori exposed to C10, GKP42, or vehicle (Fig. 2A
to C) produced similar numbers of cag T4SS pili, while treatment
with KSK85 abrogated pilus formation in themajority ofH. pylori
cells (Fig. 2D to F). A small proportion of KSK85-treatedH. pylori
formed pili, which could account for the low levels of CagA trans-
location in KSK85-treated samples (Fig. 1C; see Fig. S1E in the
supplemental material); however, the proportion of piliated cells,
as well as the number of pili produced by each bacterial cell, was
markedly reduced compared toC10-, GKP42- and vehicle-treated
samples (Fig. 2E and F).
TABLE 1 Fifty percent effective concentrations for the attenuation of
cag T4SS-dependent IL-8 secretion by peptidomimetic small moleculesa
Compound
Log EC50 (SEM)
[95% CI]
Hill slope (SEM)
[95% CI]
EC50 (M)
[95% CI]
C10 1.19 (0.0322)
[1.26 to1.12]
1.49 (0.224)
[1.95 to1.02]
64.5
[55.375.3]
KSK85 1.14 (0.0337)
[1.21 to1.07]
1.23 (0.188)
[1.62 to0.839]
72.2
[61.484.8]
C10/KSK85b 1.45 (0.0694)
[1.59 to1.30]
0.98 (0.201)
[1.40 to0.562]
35.8
[25.750]
GKP42 0.648 (0.229)
[1.12 to0.172]
3.12 (3.21)
[9.80 to 3.56]
225
[75.2673]
a Compounds were added to H. pylori-gastric epithelial cell monolayers for the duration
of the coculture experiment (4.5 h), and IL-8 secretion was evaluated by anti-human
IL-8 enzyme-linked immunosorbent assay (ELISA) as described in Text S1 in the
supplemental material. Fifty percent effective concentrations (EC50s) were calculated
from normalized IL-8 secretion levels, where IL-8 levels obtained from compound-
treated samples were expressed as a percentage of values obtained in the vehicle control
wells (0.3%DMSO, final concentration for all samples). Percentages from separate
biological replicate samples were normalized to a range of 10 to 100%, where maximal T4SS
inhibition is defined as 10% and 100% represents full T4SS activity. EC50 values were
calculated in GraphPad using nonlinear regression of normalized IL-8 secretion values
[variable slope four parameter, log(agonist) versus response]. The standard errors of the
means (SEM) are shown in parentheses for log EC50 andHill slope. The 95% confidence
intervals (95% CI) are shown in brackets for log EC50, Hill slope, and EC50.
b C10 and KSK85 were added at equal concentrations ranging from 25 M to 150 M
each.
FIG 1 Peptidomimetic small molecules disrupt activity of the H. pylori cag T4SS. (A) Compounds evaluated in this study contain a common peptidomimetic
ring-fused 2-pyridone backbone structure (shown in blue in the inset). (B and C) Effects of C10 and KSK85 on T4SS-dependent activation of IL-8 synthesis and
secretion by cultured AGS gastric epithelial cells (B) and on CagA translocation into cultured human gastric epithelial cells (150 M final compound concen-
trations assayed) (C). (C) Densitometry analysis of tyrosine-phosphorylated CagA normalized to total CagA in five independent biological replicates was
performed by ImageJ analysis. (D) Effects of C10 andKSK85 onH. pyloriT4SS-dependentNF-B activation in AGS cells. (E and F) IL-8 secretion (E) andNF-B
activation (F) stimulated by recombinant human TNF- (in the absence of H. pylori). Graphs of IL-8 secretion and NF-B activation depict the means 
standard errors of the means (SEM) (error bars) of at least three biological replicate experiments. P values in panel C were calculated by one-way ANOVA. See
also Fig. S1 in the supplemental material and Table 1.
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CagA attenuates the disruptive effects of C10 and KSK85 on
T4SS activity. Activation of NF-B signaling and induction of
IL-8 secretion can occur in response to translocated CagA and/or
peptidoglycan (16, 45). It is thus possible that C10 andKSK85 also
influence the translocation of peptidoglycan or other unidentified
effector molecules. To assess whether the inhibitory effects of the
compounds on NF-B signaling and IL-8 secretion were attribut-
able to blocking one or both types of translocation, we evaluated
the effects of KSK85 and C10 on an H. pylori cagA mutant. The
effects of C10 on H. pylori cagA mutant were the same as those
observed in the wild-type (WT) strain (Fig. 3A). These results
suggest that the inhibitory effects of C10 on NF-B activation are
primarily attributable to blocking translocation of peptidoglycan
or additional effector molecules (Fig. 3A). The ability of KSK85 to
disrupt cag T4SS-mediated NF-B activation was reduced com-
pared to the inhibitory effects of C10 (Fig. 3A versus Fig. 3B);
however, the inhibitory effects of KSK85 were significantly en-
hanced in the cagA mutant strain (P  0.004 by paired t test)
compared to the WT strain (Fig. 3B). To investigate the basis for
this phenomenon, we first analyzed whether CagA is important
FIG 2 KSK85 inhibits assembly of T4SS pili at the bacterium-host cell interface. (A to D) Field-emission scanning electronmicroscopy (FESEM) evaluating the
T4SS piliation state of H. pylori (white arrows) treated with vehicle (A), noninhibitory compound GKP42 (B), C10 (C), or KSK85 (D). Bars, 500 nm. (E)
Enumeration of T4SS pili per bacterial cell. The short black lines in panel E represent the geometric mean of each distribution. (F) Proportion of H. pylori that
elaborate T4SS pili in the presence of C10 and KSK85. The inset shows the median number of pili per bacterial cell (boxes) and the maximum number of T4SS
pili observed per individualH. pylori cell (whiskers).
Shaffer et al.
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for pilus assembly and observed that the cagAmutant produced
T4SS-associated pili at levels similar to those produced by theWT
(see Fig. S2A in the supplemental material). Thus, although
KSK85 inhibits formation of cag T4SS pili, loss of CagA does not
preclude elaboration of pilus structures that are targeted by
KSK85. In addition, the absence of CagA did not influence adher-
ence of bacteria to the gastric epithelial surfaces (Fig. S2B), indi-
cating that pilus-associated CagA does not facilitate binding of
H. pylori to target host cells. Collectively, these data suggested that
the inhibitory activity of KSK85 is reduced in the presence of
CagA, potentially through CagA-compound interactions.
H. pylori exploits the surface of gastric epithelial cells as a rep-
licative niche by using cag T4SS-dependent processes to control
cell polarity (46). Therefore, we tested the effects of the com-
pounds on replication ofH. pylori co-cultured with gastric epithe-
lial cells. In accordance with a previous report (46), fewer CFU of
a cagE mutant (deficient in an essential ATPase of the cag T4SS
and defective in pilus production) were consistently recovered
fromAGS cell co-culture at 6 h post-infection compared to recov-
ery of the WT strain, regardless of compound exposure (Fig. 3C).
ThecagEmutant exhibitedWT adherence properties (Fig. S2B),
ruling out the possibility that the differential recovery of bacteria
was attributable to differences in adherence. Similar numbers of
CFU of theWT strain and cagAmutant were recovered from con-
trol co-cultures (treated with the vehicle dimethyl sulfoxide
[DMSO]) (Fig. 3C). Interestingly, our studies revealed that the
numbers of cagA CFU recovered from co-culture at 6 h postin-
fection were reduced at least 10-fold in the compound-treated
wells compared to the control DMSO-treated bacteria (Fig. 3C).
This result indicated that loss of CagA enhances the T4SS inhibi-
tory capacity of the compounds whenH. pylori are in contact with
host cells. However, we cannot rule out the possibility that the
reduction in recovered cagA CFU stems from altered host cell
phenotypes that arise as a consequence of CagA translocation,
which may confer survival benefits to the bacterium at this host-
microbe interface.
C10 and KSK85 significantly reduce T4SS-dependent DNA
transfer in divergent proteobacteria.Given the incredible diver-
sity of T4SS across phyla with respect to both function and appa-
ratus architecture (1–3, 47), we investigated whether C10 and
KSK85 attenuate T4SS processes in other bacterial species. We
first analyzed the ability of C10 and KSK85 to prevent DNA trans-
fer through the IncN group conjugative T4SS encoded by genes
carried on pKM101 and the IncF groupR1-16 conjugative T4SS in
E. coli (7, 9). Compared to vehicle controls, C10 and KSK85 re-
duced theDNA conjugation efficiency of pKM101 in a statistically
significant manner (Fig. 4A). Compound treatment did not im-
pair E. coli growth (see Fig. S3A in the supplemental material),
suggesting that the observed decrease in numbers of transconju-
gants was not due to reduced replication of the bacteria in the
presence of compounds. Analysis of DNA conjugation efficiency
of the derepressedR1-16 system (lacking a regulatory element that
restricts DNA conjugation) demonstrated that C10 reduced DNA
transfer, whereas KSK85 did not (Fig. 4A), suggesting that R1-16
derepression can partially compensate for the T4SS inhibitory ef-
fects of KSK85.
Finally, we analyzed the ability of C10 and KSK85 to ablate
Agrobacterium vir T4SS-mediated DNA translocation into recipi-
ent plant cells using an intron-containing-glucuronidase (GUS)
gene reporter assay. Species of the genus Agrobacterium carry
genes that encode type IV conjugation systems that facilitate the
delivery of plasmid-derived transfer DNA (T-DNA) into target
plant cells (1, 2); the T-DNA is subsequently integrated randomly
into the plant cell genome. Conjugation-mediated transfer of
T-DNA from A. tumefaciens to plants can be readily monitored
using an agroinfiltration system developed for tobacco (48). This
method relies on the infiltration of A. tumefaciens into the inter-
stitial spaces of a leaf, followed by incubation to allow for T-DNA
transfer, integration of T-DNA into the nuclear DNA of trans-
formed plant cells, and T-DNA expression. In our assay, use of the
intron-GUS expression cassette permits GUS enzyme production
only by suitably transformed plant cells because A. tumefaciens
lacks the splicing machinery necessary for removal of introns.
Qualitative analysis of GUS activity can be performed by staining
using X-Gluc (5-bromo-4-chloro-3-indolyl--D-glucuronic acid,
cyclohexylammonium salt) as the substrate (see Fig. S4A in the
supplemental material). Using a fluorescence-based assay that
measures GUS enzymatic activity, we determined that T-DNA
transfer and genomic integration could be reliably measured and
quantified at 48 h post-infection.
Using this approach, we evaluated the ability of C10 and
KSK85 to prevent A. tumefaciens-mediated transfer of the GUS
FIG 3 C10 and KSK85 disrupt cag T4SS activity in the absence of CagA. (A and B) T4SS-dependent NF-B activation by WT H. pylori and H. pylori cagA
mutant in the presence of C10 (A) and KSK85 (B). The values are means  standard errors of the means (error bars) derived from four biological replicate
experiments. (C) CFU of adherentH. pylori on the surface of gastric epithelial cells at 6 h postinfection. The short black bars depict the geometric means of eight
biological replicates. The P values in panel C were calculated by two-tailed Mann-Whitney test.
Small-Molecule Type IV Secretion System Inhibitors
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intron-containing gene. Similar to results obtained using the
H. pylori cag T4SS model and E. coli conjugation systems (Fig. 1
and 4A), C10 significantly reduced GUS production compared to
either DMSO-treated or GKP42-treated controls (Fig. 4B). In
contrast, KSK85 did not prevent T-DNA transfer, consistent with
previous studies indicating that the vir pilus appendage is dispens-
able for T-DNA translocation (26).A. tumefaciens growth was not
impaired in the presence of C10 or KSK85 at concentrations up to
450M(see Fig. S3B in the supplementalmaterial). In parallel, we
utilized a qualitative carrot disk tumor formation assay to evaluate
the inhibitory effects of the compounds onA. tumefaciens virT4SS
activity (49). We found that carrots impregnated with 150 M
C10 prior to inoculation with A. tumefaciens developed markedly
fewer tumors compared to carrots treated with KSK85 and vehicle
controls (Fig. S4B). Although the carrot disk assay does not allow
for an evaluation of the half-lives of compounds during the period
of carrot disk incubation or an assessment of the viability of A. tu-
mefaciens infiltrated within carrot disks over the course of tumor
formation, the effects of C10 in preventing tumor formation mir-
rored the decreased levels of T-DNA transfer measured in C10-
treated leaves in our tobacco plant infection model. Collectively,
our studies identified two compounds, C10 and KSK85, that ex-
hibit inhibitory activity toward T4SS function in diverse bacteria.
DISCUSSION
Type IV secretion systems are incredibly diverse nanomachines
that vary in function and complexity across bacterial phyla (1, 2).
The versatility of T4SS function confers a range of fitness advan-
tages that significantly contribute to bacterial genome plasticity,
pathogenic potential, and bacterial survival within distinct envi-
ronments (2). Thus far, there have been relatively few studies
aimed at developing inhibitors of T4SSs (29–32, 50), and previous
studies largely relied on high-throughput screening methodolo-
gies to target one specific T4SS component. The intrinsic com-
plexity of these multicomponent systems and the lack of detailed
understanding of cag T4SS biogenesis mechanisms in H. pylori
favor the use of a phenotypic screen to identify potential small-
molecule modulators. Here, we identified two compounds from
our focused peptidomimetic library that interfere with T4SS-
dependent delivery of both protein and DNA cargo in diverse
proteobacteria.
Understanding the process of theH. pylori cag T4SS apparatus
assembly will undoubtedly require many years of investigation;
utilizing chemical probes such as C10 and KSK85 will greatly aug-
ment current efforts. For example, our field-emission scanning
electron microscopy (FESEM) studies indicated that while C10
does not prevent assembly of the cag T4SS-associated pilus,
KSK85 significantly inhibits T4SS pilus biogenesis (Fig. 2). Re-
markably, these compounds differ by a single methoxy group on
the naphthyl substituent of the 2-pyridone ring (Fig. 1A). Both
compounds reduced cag T4SS-dependent IL-8 secretion and
NF-B activation by WT H. pylori (Fig. 1), yet KSK85 exhibited
greater inhibitory disruption of T4SS activity in a cagA mutant
(Fig. 3). Further studies are under way to dissect the basis for
functional differences between the two compounds. Moreover,
the identified compounds were modestly effective at reducing
T4SS-related activity (Table 1), and thus, they can serve as proto-
typical scaffolds for further development of compounds that tar-
get cag T4SS activity.
The observation that only a small subset of individuals colo-
nized by H. pylori develop severe gastric disease is reflective of a
finely regulated host-microbe coevolution spanning many thou-
sands of years (13, 51, 52). Injection of CagA into gastric epithelial
cells likely provides several colonization advantages to H. pylori.
The role of CagA as a eukaryotic signaling mimetic with the ca-
pacity to interact with multiple intracellular host cell components
signifies a specialized function of this bacterial effector and high-
lights the integral contribution of the cagT4SS deliverymachinery
in mediating pathogenesis (11, 53, 54). A recent study described
how translocated CagA allows H. pylori to usurp the surface of
gastric epithelial cells as a replicative niche (46). Using C10 and
KSK85 as molecular probes, we provide additional evidence that
T4SS-dependent processes are important forH. pylori viability on
the surfaces of gastric epithelial cells in vitro (Fig. 3C). Thus, these
results highlight the utility of these chemical probes in dissecting
pathogenicity determinants that contribute to bacterial coloniza-
tion of the host.
FIG4 Peptidomimetic smallmolecules target diverse type IV secretion systems. (A)DNA conjugation efficiency by the pKM101 andR1-16 gene-encodedT4SSs
in the presence of C10, KSK85, or GKP42 (150 M assayed). Results represent mean conjugation efficiencies plus SEM for five independent experiments. (B) A
fluorescence-based assay was used to quantify -glucuronidase activity of Nicotiana benthamiana zones coinfiltrated with A. tumefaciens GV3101 pCAMBIA::
GUS andDMSO, C10, KSK85, or GKP42 at the indicated concentrations. Values aremeans plus SEMof three biological replicates containing at least three leaves
with multiple zones of agroinfiltration per leaf per biological replicate. P values were calculated by one-way ANOVA with Dunnett’s posthoc correction for
multiple comparisons.
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When studying the effects of KSK85 and C10 on E. coli conju-
gation efficiency and on the vir T4SS harbored by A. tumefaciens,
we observed that compared to KSK85, C10 was a more potent
inhibitor of DNA transfer (Fig. 4A and B). There are multiple
possible explanations for this observation. One possibility, given
that previous studies have shown that the vir pilus appendage is
not essential for DNA translocation into the plant cell (26, 27) is
that KSK85 preferentially inhibits T4SSs that require the elabora-
tion of a pilus to translocate their cargo. Conversely, since C10 is a
more potent inhibitor of type IV secretion in a broad range of
bacterial species, we hypothesize that C10 impacts a process inde-
pendent of T4SS pilus biogenesis that is essential for T4SS cargo
transport. In future investigations, it will be important to explore
how these small molecule inhibitors may alter the synthesis or
accumulation of T4SS protein components during apparatus bio-
genesis.
While we identified these small molecules as chemical probes
to interrogate H. pylori cag T4SS biogenesis, our findings provide
a foundation for the potential development of H. pylori-specific
anti-virulence strategies (Fig. 1, Table 1, and Fig. 3). The cag T4SS
harbored by H. pylori is one of the most significant virulence de-
terminants associated with development of severe gastric disease
(53, 55, 56). CagA, the only identified effector protein known to be
injected into host gastric epithelial cells byH. pylori, is a bona fide
oncoprotein that hijacks host cell signaling pathways to promote
carcinogenesis (11, 53, 56, 57). The development of compounds
that disarm cag T4SS-mediated processes may lead to new strate-
gies for mitigating the threat associated with H. pylori-induced
carcinogenesis in populations at high risk for developing gastric
cancers (13). In this study, we identified 2-pyridone compounds
that interfere with CagA translocation (Fig. 1C) and additionally
block cag T4SS activity in a CagA-independent manner (Fig. 3).
Interestingly, the efficacy of KSK85 against the cag T4SS was en-
hanced in a CagA mutant strain, which raises the possibility that
KSK85 can interact with this oncoprotein. We speculate that the
highly abundant CagA protein can serve as a protein sink within
H. pylori, thereby sequestering compounds such as KSK85 away
from cellular targets, leading to attenuation of T4SS inhibitory
effects. We propose that CagA interacts with KSK85 to titrate the
compound away from other cellular targets that are involved in
T4SS function, while also preventing biogenesis of cag T4SS-
associated pili in a CagA-independentmanner. These compounds
could potentially segregate CagA to bacterial compartments and
serve as potential therapeutics; we are currently investigating the
underlying mechanism for this observation.
The explosive emergence of antibiotic resistance among clini-
cally significant bacterial populations highlights the critical role of
T4SSs in the rapid propagation and exchange of mobile genetic
elements (2). Resistance to current therapies continually arises
due to selective pressure for bacteria to circumvent the bacteri-
cidal actions of antibiotics, and this poses a serious threat to public
health. Rather than targeting essential cellular functions that ulti-
mately kill the bacterium, utilizing compounds that reprogram
and/or abort processes such as T4SS-mediated genetic exchange
represents an attractive new avenue for drug development. Like-
wise, compounds that specifically target DNA conjugation would
critically impact the rate and frequency of horizontal gene transfer
in “hot spots” for this phenomenon (50), such as the gastrointes-
tinal tract, without significantly altering the gross ecology of the
host microflora. In summary, we present two structurally related
compounds that impact T4SS-mediated processes involved in vir-
ulence factor secretion and dissemination of plasmid-borne anti-
biotic resistance markers. Thus, these compounds are excellent
molecular scaffolds that can be exploited in the development of
versatile chemical tools to dissect and disarm these important
nanomachines.
MATERIALS AND METHODS
Synthesis of ring-fused 2-pyridones. Complete synthetic methods and
schemes are presented in Text S1 in the supplemental materials.
Bacterial strains and growth conditions.H. pylori strains 26695,G27,
98-10, and isogenic 26695mutants (19, 20) were grown on Trypticase soy
agar supplemented with 5% sheep blood (BD Biosciences) or brucella
broth supplemented with 5% fetal bovine serum (FBS) at 37°C in 5%
atmosphere CO2. E. coli MG1655 harboring the conjugative plasmid
pKM101, E. coli MS411 harboring the R1-16 conjugative plasmid, and
E. coliWM1652 recipient cells were grown on lysogeny broth (LB) agar or
broth supplemented with ampicillin (50 g/ml), kanamycin (50 g/ml),
or tetracycline (20 g/ml), respectively. Agrobacterium tumefaciens C58
and its derivative GV3101 were maintained on LB plates supplemented
with rifampin (25 g/ml) at 28°C. A. tumefaciens GV3101 harboring
pCAMBIA vectors were maintained on LB containing rifampin (25 g/
ml) and kanamycin (100 g/ml).
Cell culture. AGS human gastric epithelial cells and the AGS NF-B
luciferase reporter cell line (21) were grown in 5% CO2 in RPMI 1640
medium supplemented with 10% FBS, 2 mM L-glutamine, and 10 mM
HEPES buffer (complete RPMI).
Cell viability assays. H. pylori, A. tumefaciens, E. coli, or human cell
lines were grown in complete RPMI or brucella broth supplemented with
the indicated compounds or dimethyl sulfoxide (DMSO) for 6 to 24 h.
Cell viability was assessed using CellTiter-Glo (Promega) according to the
manufacturer’s protocol.
IL-8 induction assays. Quantitation of IL-8 secretion by gastric epi-
thelial cells in contact with H. pylori was performed as previously de-
scribed (20) and in Text S1 in the supplemental material.
Quantitation of NF-B signaling activation. AGS cells stably trans-
fected with an NF-B-luciferase reporter (AGS NF-B-luc) (21) were
cultured for 24 h and treated as described for the IL-8 induction assays.
After 4 h of coculture with H. pylori, cell monolayers were washed with
sterile phosphate-buffered saline (PBS), and cell monolayer extracts were
obtained by passive cell lysis. NF-B-luciferase activity was measured by
the Steady-Glo luciferase assay system (Promega) on a BioTek Synergy 4
plate reader, and plates were normalized to the DMSO vehicle control for
each dilution series. AGS NF-B-luc cells exposed to compounds in the
absence of H. pylori were stimulated for 1 h with 10 ng/ml TNF- and
assayed by the Steady-Glo system to validate that compounds do not
impact NF-B signaling.
CagA translocation assay. Translocation of CagA into AGS cells was
analyzed as described in reference 20 and Text S1 in the supplemental
material.
Scanning electron microscopy. Overnight cultures of H. pylori were
diluted to an optical density at 600 nm (OD600) of ~0.3 and incubated
with shaking at 37°C and 5% CO2 for 1 h in the presence of vehicle or
150 M compound and cocultured with AGS cells on tissue culture-
treated coverslips (BD Biosciences) at amultiplicity of infection (MOI) of
100 in the presence of 150 M compound or vehicle. H. pylori-AGS cell
co-cultures were processed and imaged as described in references 19, 20,
and 21 and Text S1 in the supplemental material.
H. pylori viability in AGS cell coculture. H. pylori pretreated with
compound were added to AGS cells at an MOI of 100 in the presence of
150 M compound and treated as described for IL-8 induction studies.
After 6 h of coculture, RPMI 1640 medium was aspirated, and the wells
were washed five times with sterile PBS to remove non-adherent bacteria.
AGS cells with adherentH. pylori were dislodged in sterile PBS, and serial
dilutions were plated to determine the number ofH. pyloriCFU.H. pylori
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survival experiments were performed at least three times with four repli-
cate wells per experimental condition.
Analysis ofDNA conjugation efficiency.Overnight cultures of donor
E. coli MG1655 harboring pKM101, donor E. coli MS411 harboring R1-
16, and recipient E. coliMG1655 (WM1652) bacteria were grown at 37°C
with shaking at 225 rpm in LB plus antibiotic, diluted in antibiotic-free LB
containing DMSO or 150 M compound, and incubated with shaking at
37°C to reach anOD600 of ~0.3. Donor and recipient cells weremixed at a
ratio of 1:1 on 0.22-m-pore-sizemixed-cellulose-ester filters (Millipore)
on antibiotic-free LB plates for 2 h at 37°C. Filters were aseptically re-
moved from LB plates and incubated in 100 l antibiotic-free LB to dis-
lodge E. coli from membranes. Serial dilutions were plated on the appro-
priate antibiotic (or dual-antibiotic) LBplates to determine the number of
donor, recipient, and transconjugant cells. Colonies were enumerated af-
ter 24 h, and conjugation efficiencies were calculated by dividing the av-
erage number of transconjugates by the average number of donors (either
pKM101 or R1-16 donor cells). Conjugation efficiency in the presence of
compound is expressed as a percentage of conjugation efficiency in
DMSO. Data represent six individual experiments for compounds C10
and KSK85 and three individual experiments for GKP42.
Agroinfiltration and GUS assays. Agroinfiltration and -glu-
curonidase (GUS) fluorometric assays were performed as previously de-
scribed (58, 59). Extensive experimental protocols are presented in
Text S1 in the supplemental material.
Carrot disk tumor formation assay.Whole carrots were sterilized by
soaking in 20% bleach for 30 min and subsequently sliced into disks of
approximately 8 to 10 mm. The apical surface of each disk was placed on
water agar (1.5%) medium containing no additional nutritional supple-
mentation. Carrot disks were incubatedwith 100l of eitherDMSO,C10,
KSK85, or GKP42 (final concentration of all compounds at 150 M) in
sterile PBS for 1 h to allow for the uptake of compounds into the carrot
tissue. Replicate carrot disks were inoculated with 20 l Agrobacterium
tumefaciens C58 harvested from logarithmic-phase growth (OD600 of
~0.8) that had been pretreated for 1 h with shaking at 28°C in LB contain-
ing DMSO, C10, KSK85, or GKP42 (each compound at a final concentra-
tion of 150 M). The plates were sealed with Parafilm and stored in the
dark at room temperature for 3 weeks. Carrot tumors were photographed
at 21 days postinoculation. Images are representative of at least five indi-
vidual carrot disks.
Statistical analysis. Statistical analyses were performed using Graph-
Pad Prism 6. Data are expressed as the mean  standard error. Data
comparisons from more than two groups were analyzed by analysis of
variance (ANOVA) followed by Dunnett’s posthoc test for multiple com-
parisons against a single control (vehicle-treated samples).
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org/
lookup/suppl/doi:10.1128/mBio.00221-16/-/DCSupplemental.
Text S1, DOCX file, 0.1 MB.
Figure S1, TIF file, 1.3 MB.
Figure S2, TIF file, 4.1 MB.
Figure S3, TIF file, 5.4 MB.
Figure S4, TIF file, 3.6 MB.
Table S1, DOCX file, 0.3 MB.
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